| 程序性死亡受体1及程序性死亡受体配体1抑制剂在小细胞肺癌治疗中的进展 |
| |
| 引用本文： | 张姝阳,王燕. 程序性死亡受体1及程序性死亡受体配体1抑制剂在小细胞肺癌治疗中的进展[J]. 中华肿瘤杂志, 2021, 0(1): 98-103 |
| |
| 作者姓名： | 张姝阳 王燕 |
| |
| 作者单位： | 国家癌症中心 |
| |
| 基金项目： | 中国医学科学院医学与健康科技创新工程 (2019-I2M-2-003)。 |
| |
| 摘 要： | 小细胞肺癌(SCLC)约占肺癌的15%,是一种神经内分泌肿瘤,生长迅速、极具侵袭性,容易早期发生远处转移。尽管SCLC对一线化疗敏感,但容易短时间内复发。在过去的5年间,免疫治疗在SCLC中取得了一定的成果,特别是在程序性死亡受体1和程序性死亡受体配体1方面,SCLC治疗模式已经发生改变。文章对免疫检查点抑制剂在SCLC中的探索研究做一综述,以期为广大临床工作者提供参考。
|
| 关 键 词： | 癌,小细胞肺 免疫检查点抑制剂 程序性死亡受体1 程序性死亡受体配体1 |
Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer |
| |
| Zhang Shuyang,Wang Yan. Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer[J]. Chinese Journal of Oncology, 2021, 0(1): 98-103 |
| |
| Authors: | Zhang Shuyang Wang Yan |
| |
| Affiliation: | (Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China) |
| |
| Abstract: | Small cell lung cancer(SCLC)is a neuroendocrine tumor,which accounts for about 15%of all lung cancers.SCLC is characterized by rapid growth and tendency to widespread metastasis at the initial stage.Although high response rates to first-line chemotherapy are observed,most patients relapse less than few months.In the past 5 years,some clinical trials found that the immune checkpoint inhibitors(ICIs)were effective in SCLC,especially programmed cell death 1/ligand 1(PD-1/L1).Given this situation,the treatment patterns of SCLC have changed.This article briefly reviews the researches and studies of ICIs in the treatment of SCLC to provide reference to the clinicians. |
| |
| Keywords: | Carcinoma,small cell lung Immune checkpoint inhibitors Programmed cell death 1 Programmed cell death-ligand 1 |
| 本文献已被 维普 等数据库收录！ |
|
